PocketEdge
PocketEdge
NewsResearchPortfolioAdvisorsGuidesToolsAI
Ask AI
PocketEdge

Markets, research, advisors, guides, and tools. Understand what is happening, and what to do next.

Explore

  • News
  • Research
  • Advisors
  • Guides
  • Tools
  • Ask AI

© 2026 PocketEdge

PrivacyTermsLegal

Not investment advice. Verify with licensed professionals.

← All news

Desk note · industry · Food safety / e-commerce

India’s food regulator just called out protein drinks sold on Amazon and Flipkart

On 8 October 2026, FSSAI issued notices to Dr Reddy’s, Nestle Health Science, Tirupati Wellness, Amazon, Flipkart, and Netmeds over Celevida GLP marketing. The regulator said pack claims about muscle, immunity, and GLP-1 therapies could mislead shoppers.

8 Oct 2026 · 2 min read

Key takeaways

  • •Notices on 8 October 2026 covered Celevida GLP sold on major e-commerce and pharmacy platforms.
  • •FSSAI flagged claims tying the product to GLP-1/GIP therapies and lean muscle preservation.
  • •Named parties include Dr Reddy’s, Nestle Health Science, Amazon, Flipkart, and Netmeds.

What's going on here?

On 8 October 2026, the Food Safety and Standards Authority of India said it sent notices to Dr Reddy’s, Nestle Health Science, Tirupati Wellness, Amazon, Flipkart, and Netmeds. The case centres on Celevida GLP, a health supplement sold online. FSSAI posted on social media that advertising described the drink as high-protein support during GLP-1 and GIP therapies. Pack claims mentioned muscle strength, immunity support, and energy metabolism. The regulator said those claims could mislead buyers about what the product actually does.

What does this mean?

GLP-1 weight-loss drugs have moved from clinics into dinner-table conversation. Supplement makers often market protein powders and drinks beside that trend. FSSAI is drawing a line between food products and drug-linked promises. When a listing sits on Amazon or Flipkart, the platform and the brand both face questions about who checked the label. This is enforcement, not a new tax or ban. Shelves may stay stocked while companies respond to the notices.

Why should I care?

If you buy protein drinks or wellness powders online, read the label and the fine print on the listing. A product that mentions GLP-1 therapies is making a serious health claim. If you sell food or supplements, expect more scrutiny on marketplace copy, not just factory standards. Watch whether FSSAI widens the sweep beyond this SKU and whether platforms tighten listing rules after the notices.

More desk notes

Telecom / IPO

Jio Platforms’ IPO filled its retail quota on the second day of bidding

On 22 October 2026, exchange data showed Jio Platforms’ ₹30,213 crore issue had drawn about ₹3.73 lakh crore of total bids by late evening on Day 2, with the retail portion oversubscribed and market commentators citing diverted cash from other listed stocks during the book build.

SEBI / market infrastructure

SEBI wants exchanges to invest in related businesses without case-by-case approval

On 22 October 2026, the Securities and Exchange Board of India proposed letting stock exchanges and depositories fund core-market and regulator-mandated initiatives without prior approval for each ticket, while keeping board oversight and financial safeguards and inviting comments until 12 November.

E-commerce / food delivery

Flipkart is piloting a food delivery service for thousands of Bengaluru staff

On 22 October 2026, reporting said Flipkart is testing an internal food delivery product called Eat-in by Minutes with more than 8,000 employees in Bengaluru, using Ekart logistics as it prepares to compete with Zomato and Swiggy in meal delivery.

Digital trust / compliance

eMudhra’s board voted to leave the global website certificate business

On 22 October 2026, eMudhra Ltd said its board will voluntarily withdraw from the global SSL/TLS certificate segment after a key-security incident on eight intermediate certificates, citing compliance cost and weak economics while stressing that other digital-trust services continue.

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.